XML 62 R46.htm IDEA: XBRL DOCUMENT v3.5.0.2
INTANGIBLE ASSETS (Details) - USD ($)
6 Months Ended 12 Months Ended
Sep. 30, 2016
Mar. 31, 2016
Finite-Lived Intangible Assets [Line Items]    
Accumulated Amortization $ 0 $ 0
Gross Carrying Amount Total 6,411,799 6,381,774
Additions, Total 6,033 30,025
Net Book Value, Total $ 6,417,832 $ 6,411,799
Patent Application Cost [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated Useful Life [1] 0 years 0 years
Patent application costs, Gross Carrying Amount $ 364,482 $ 334,457
Patent application costs, Additions 6,033 30,025
Accumulated Amortization 0 0
Net Book Value 370,515 364,482
ANDA Acquisition Cost [Member]    
Finite-Lived Intangible Assets [Line Items]    
ANDA acquisition costs, Gross Carrying Amount 6,047,317 6,047,317
ANDA acquisition costs, Additions 0 0
Accumulated Amortization 0 0
Net Book Value $ 6,047,317 $ 6,047,317
[1] Patent application costs were incurred in relation to the Company’s abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the Food and Drug Administration (“FDA”). Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s).